January 12, 2023
As many as 10 Humira biosimilars may be on the US market before 2023 is over. AbbVie has taken several steps to protect its revenues, including the launches of Skyrizi and Rinvoq.
December 22, 2022
Take a look back at our most popular biosimilars coverage for 2022.
December 15, 2022
Biosimilar medications stand to significantly increase cost savings for patients.
October 13, 2022
From biosimilars to artificial intelligence, these are the trends poised to take community pharmacy by storm.
September 28, 2022
The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
September 15, 2022
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
September 13, 2022
Several provisions in the law are designed to protect and foster the biosimilar market. But some representatives of the sector see CMS drug price negotiation as a threat to profit margins.
September 12, 2022
Some companies are using the interchangeability designation as a marketing ploy.
August 26, 2022
Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.
August 16, 2022
New research should give expectant mothers some peace of mind.
